BioStock published an article on 9 March 2022 about Aptahem, which can be read in full below. Aptahem has communicated several positive news lately. Recently, the company received patent protection in Japan for patent family 2 regarding the drug...
Read MoreAptahem announces today that the production of Good Manufacturing Practice (GMP) manufacturing of the drug candidate Apta-1 successfully has been prepared by the collaboration partner LGC Biotechnologies in the USA, according to timeplan. The GMP manufactured Apta-1 will be...
Read MoreVD kommenterar Det har blivit dags för ett nyhetsbrev från Aptahem med de senaste uppdateringarna kring vårt arbete med att ta vår läkemedelskandidat Apta-1 in i nästa utvecklingssteg för att utvärdera dess potential som en framtida behandling för sepsis...
Read More